STOCK TITAN

Mustang Bio Inc - MBIO STOCK NEWS

Welcome to our dedicated news page for Mustang Bio (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mustang Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mustang Bio's position in the market.

Rhea-AI Summary
Mustang Bio announces FDA acceptance of IND application for MB-109, a combination therapy for recurrent glioblastoma and high-grade astrocytoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.19%
Tags
-
Rhea-AI Summary
Mustang Bio, Inc. announced participation in two investor conferences in New York City.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
conferences
-
Rhea-AI Summary
Mustang Bio, Inc. (MBIO) announced positive initial data from the indolent lymphoma cohort of its Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy. The data showed clinical responses in all four patients, including a complete response in a follicular lymphoma patient previously treated with CD19 CAR-T cell therapy. The Safety Review Committee also approved dose escalation, indicating the therapy's potential for a wide range of hematologic malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
Rhea-AI Summary
Mustang Bio, Inc. announced financial results for Q2 2023, with cash and cash equivalents totaling $16.1 million. They continued to advance the development of their lead clinical candidate MB-106, a CAR T cell therapy for B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. They also announced a strategic transaction and partnership with uBriGene Biosciences Inc., which will reduce operating expenses by at least $28 million. Mustang's lead candidate, MB-106, showed promising results in treating Waldenstrom macroglobulinemia and follicular lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.56%
Tags
partnership
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.78%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.54%
Tags
partnership
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Mustang Bio Inc

Nasdaq:MBIO

MBIO Rankings

MBIO Stock Data

5.28M
6.43M
22.77%
11.11%
1.71%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About MBIO

mustang bio, inc., a subsidiary of fortress biotech, inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. mustang has partnered with the city of hope national medical center (“coh”) and fred hutchinson cancer research center in the development of proprietary chimeric antigen receptor (car) engineered t cell (car t) therapies across many cancers. mustang’s lead programs are in phase 1 clinical trials at coh: mb-101 for the treatment of brain cancer and mb-102 as a therapeutic agent in acute myeloid leukemia.